USPTO serial 99623102
AIKA
Reviewed by CopyMark Law Group
Status 681
- Filing date
- Status date
- Registration date
- —
- Examiner
- GUTTADAURO, JULIE MARIE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AIKA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew T. Rissler
Andrew T. Rissler Patel IP, P.C.20700 Ventura Blvd., Suite 235Woodland Hills, CA 91364United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable computer software using artificial intelligence models for drug discovery, efficacy analysis of drugs and diagnostic agents, efficacy analysis of medical diagnostics, efficacy analysis of biological products and functional materials used in bio-medicine, and for use in providing advice on testing, research and development on pharmaceuticals, regenerative medicine products, cosmetics, foods, agricultural chemicals and functional materials used in bio-medicine; downloadable computer software with artificial intelligence used for drug discovery screening | ACTIVE | — |
| 038 | Lease of access time to computer databases | ACTIVE | — |
| 042 | Providing online non-downloadable computer software using artificial intelligence for drug discovery screening; providing online non-downloadable computer software using artificial intelligence for analysis, testing, screening, design and research of chemicals, pharmaceuticals and functional materials used in bio-medicine; screening for scientific research purposes and design of chemical compounds acting on drug targets; biochemical analysis and design of compounds for use in pharmaceuticals; drug screening for scientific purposes of chemical compounds used in pharmaceuticals; scientific analysis, scientific testing, design, scientific research and drug screening for scientific purposes of chemicals, pharmaceuticals, and functional materials used in bio-medicine; scientific research and development by contracted parties in the field of drug discovery, drugs, diagnostic agents, medical diagnostics, biological products and functional materials used in bio-medicine; advice on scientific testing, research and development of pharmaceuticals, regenerative medicine products, cosmetics, foods, agricultural chemicals and functional materials used in bio-medicine; Advice and consulting about scientific testing, scientific research, and scientific feasibility studies of pharmaceuticals, regenerative medicine, cosmetics, foods, agricultural chemicals, and functional materials used in bio-medicine; electronic data storage in the nature of leasing of storage space on Internet servers; cloud computing featuring software for use in clinical trial protocol design and feasibility analysis, and for optimizing drug development processes using artificial intelligence; provision of online non-downloadable computer programs for use in advanced data analysis, predictive modeling, and regulatory planning for clinical trials and drug development; design, creation, and maintenance of computer programs, and leasing of computers; Research and development of software using artificial intelligence; testing, inspection, or research of pharmaceuticals, cosmetics, or foods; design, creating and maintenance of computer programs for design, development and research of compounds which are a source of pharmaceuticals; providing temporary use of online non-downloadable computer programs for design, development and research of compounds which are a source of pharmaceuticals; design, creating and maintenance of computer programs for design, development, research and testing of chemicals, pharmaceuticals and chemical compounds; providing temporary use of online non-downloadable computer programs for design, development, research and testing of chemicals, pharmaceuticals and chemical compounds; design, creating and maintenance of computer programs for screening for development of new drugs; providing temporary use of online non-downloadable computer programs for screening for development of new drugs; computer programming; providing temporary use of online non-downloadable computer programs for use in clinical trial protocol design and feasibility analysis, and for optimizing drug development processes using artificial intelligence; research in the field of artificial intelligence | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 14, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 22, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 8, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 8, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 8, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 28, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| May 22, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 29, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 29, 2026 | NWAP | NEW APPLICATION ENTERED | — |